Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 94Esophageal Neoplasms 88Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Neoplasms 42Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Adenocarcinoma 30Gastrointestinal Neoplasms 29Liver Neoplasms 25Esophageal Squamous Cell Carcinoma 23Carcinoma, Non-Small-Cell Lung 18Bile Duct Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 13Locally Advanced Rectal Cancer 13Colorectal Cancer Metastatic 11Appendiceal Neoplasms 11Recurrence 10Peritoneal Neoplasms 10Ovarian Neoplasms 9Carcinoma 7Breast Neoplasms 7Neurotoxicity Syndromes 6Gastrointestinal Diseases 6

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paresthesia × Oxaliplatin × Gastrointestinal × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡